meRfi®-GM
Breast Cancer / Mammacarcinoma
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
In patients newly diagnosed with Breast Cancer, also known as Mammacarcinoma, distant metastases are found in 6% or more of cases. Within this scenario, it has been suggested that locoregional therapy targeting the intact primary tumor might enhance overall survival (OS). However, clinical trials have yielded conflicting results regarding this hypothesis.
Breast Cancer / Mammacarcinoma incidence and mortality rates vary widely across the world
Since 2004, there has been a rise in the incidence of invasive Breast Cancer / Mammacarcinoma among adolescents and young adults in the United States. This increase is largely attributed to a higher number of young women being diagnosed with distant disease. In the U.S., one out of…
References (Sources)
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
- Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (E2108)
- Global Cancer Observatory: cancer today
- How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.
- Medical management of brain metastases & leptomeningeal disease in pts with breast carcinoma
- Role of autophagy in breast cancer and breast cancer stem cells (Review)
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases